Coherus Oncology (CHRS) Change in Account Payables (2013 - 2026)

Coherus Oncology has disclosed Change in Account Payables across 14 years of filings, most recently posting $2.6 million for Q1 2026.

• Change in Account Payables for Q1 2026 came in at $2.6 million, down 80.34% year-over-year; the trailing twelve-month figure through Mar 2026 was -$30.0 million (down 453.84% YoY), and the FY2025 annual result was -$19.6 million, down 396.6% from the prior year.
• Change in Account Payables came in at $2.6 million for Q1 2026 at Coherus Oncology, up from -$5.1 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $39.5 million in Q2 2024 to a low of -$50.4 million in Q3 2024.
• The 5-year median for Change in Account Payables is $1.6 million (2022), against an average of -$101058.8.
• Across the five-year window, Change in Account Payables surged 2243.35% in 2022 and sank 845.04% in 2024, its largest moves.
• Coherus Oncology's Change in Account Payables stood at $1.6 million in 2022, then slumped by 149.03% to -$785000.0 in 2023, then jumped by 907.9% to $6.3 million in 2024, then sank by 180.23% to -$5.1 million in 2025, then jumped by 150.39% to $2.6 million in 2026.
• The last three Change in Account Payables figures came in at $2.6 million (Q1 2026), -$5.1 million (Q4 2025), and -$15.3 million (Q3 2025), per Business Quant data.